An analysis of XXXX efficacy and toxicity after liver transplantation.

@entity1 @entity8 @entity101 @entity500 @entity1157 @entity648 @entity205 @entity492 @entity1011 @entity617
The use of @entity205 long term after orthotopic liver transplantation has been analyzed in 73 adults with particular reference to the dose of drug used, either alone or in combination with other immunosuppressive agents, and the side effects observed. The first 22 @entity1 were given @entity205 10 mg/kg/day for up to 2 years, but thereafter in these, and in all the other @entity1 , the drug dose was regulated by whole blood trough levels. The proportion of @entity1 maintained on @entity205 alone increased from 11% at 3 months to 54.9% and 55.6% at 3 and 4 years, respectively. The dose of @entity617 used in combination with @entity205 was lower than that used with @entity500 (P less than 0.05) up to 12 months after transplantation, but thereafter no significant difference was found. Acute cellular rejection was seen in 5 @entity1 and in all instances was related to cessation of @entity205 , while 10 @entity1 developed chronic graft rejection manifested by the @entity1157 . At 12 months and onward, 54.5-73.3% of @entity1 had normal serum @entity648 levels, and 47.6-80.0% had @entity492 aminotransferase levels in the normal range. @entity205 was discontinued in 12 @entity1 , in 8 cases because of @entity8 or @entity101 . A trend toward rising serum @entity1011 levels was seen, and after 4 years on @entity205 none of 12 @entity1 had normal levels, and these exceeded 200 mumol/L in 5. The rise in @entity1011 levels was probably in part related to the higher doses used early in the study period. The incidence of @entity101 progressively increased from 15.3% at 3 months to 63.6% at 4 years in @entity1 maintained on @entity205 .
